These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 12515564)

  • 1. Newer drugs for the treatment of lupus nephritis.
    Kuiper-Geertsma DG; Derksen RH
    Drugs; 2003; 63(2):167-80. PubMed ID: 12515564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Progress and perspectives in the treatment of systemic lupus erythematosus].
    Robak E; Sysa-Jedrzejowska A; Wozniacka A
    Przegl Lek; 2005; 62(9):894-9. PubMed ID: 16541725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic options for resistant lupus nephritis.
    Mok CC
    Semin Arthritis Rheum; 2006 Oct; 36(2):71-81. PubMed ID: 16884971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring new territory: considering the future.
    Schneider M
    Lupus; 2007; 16(3):221-6. PubMed ID: 17432111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modern therapeutic strategies for paediatric systemic lupus erythematosus and lupus nephritis.
    Marks SD; Tullus K
    Acta Paediatr; 2010 Jul; 99(7):967-74. PubMed ID: 20222881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment options for proliferative lupus nephritis: an update of clinical trial evidence.
    Navaneethan SD; Viswanathan G; Strippoli GF
    Drugs; 2008; 68(15):2095-104. PubMed ID: 18840001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction therapy with short-term high-dose intravenous cyclophosphamide followed by mycophenolate mofetil in proliferative lupus nephritis.
    Arends S; Berden JH; Grootscholten C; Derksen RH; Berger SP; de Sévaux RG; Voskuyl AE; Bijl M;
    Neth J Med; 2014 Nov; 72(9):481-90. PubMed ID: 25431394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of multitarget therapy with cyclophosphamide and tacrolimus for lupus nephritis: a prospective, single-arm, single-centre, open label pilot study in Japan.
    Sakai R; Kurasawa T; Nishi E; Kondo T; Okada Y; Shibata A; Nishimura K; Chino K; Okuyama A; Takei H; Nagasawa H; Amano K
    Lupus; 2018 Feb; 27(2):273-282. PubMed ID: 28683654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lupus-nephritis--diagnosis and treatment].
    Norby GE; Lerang K; Holdaas H; Gran JT; Strøm EH; Draganov B; Os I; Hartmann A; Gilboe IM
    Tidsskr Nor Laegeforen; 2010 Jun; 130(11):1140-4. PubMed ID: 20531500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the management of lupus nephritis: let the treatment fit the patient.
    Bertsias G; Boumpas DT
    Nat Clin Pract Rheumatol; 2008 Sep; 4(9):464-72. PubMed ID: 18756272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolate mofetil for lupus nephritis: an update.
    Mok CC
    Expert Rev Clin Immunol; 2015; 11(12):1353-64. PubMed ID: 26364748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of lupus nephritis.
    Jaryal A; Vikrant S
    Indian J Med Res; 2017 Feb; 145(2):167-178. PubMed ID: 28639592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential therapies for proliferative lupus nephritis.
    Contreras G; Pardo V; Leclercq B; Lenz O; Tozman E; O'Nan P; Roth D
    N Engl J Med; 2004 Mar; 350(10):971-80. PubMed ID: 14999109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].
    Petrović R; Stojanović R; Novicić-Sasić D; Dimitrijević J; Pavlović S; Stojković D; Palić-Obradović D; Stevanović G; Prodanović S
    Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():19-25. PubMed ID: 12583309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study.
    Boletis JN; Marinaki S; Skalioti C; Lionaki SS; Iniotaki A; Sfikakis PP
    Nephrol Dial Transplant; 2009 Jul; 24(7):2157-60. PubMed ID: 19179411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial.
    Kamanamool N; Ingsathit A; Rattanasiri S; Ngamjanyaporn P; Kasitanont N; Chawanasuntorapoj R; Pichaiwong W; Anutrakulchai S; Sangthawan P; Ophascharoensuk V; Avihingsanon Y; Sumethkul V
    Lupus; 2018 Apr; 27(4):647-656. PubMed ID: 29105558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacotherapy of lupus nephritis in children: a recommended treatment approach.
    Adams A; MacDermott EJ; Lehman TJ
    Drugs; 2006; 66(9):1191-207. PubMed ID: 16827597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimum therapeutic approaches for lupus nephritis: what therapy and for whom?
    Boumpas DT; Sidiropoulos P; Bertsias G
    Nat Clin Pract Rheumatol; 2005 Nov; 1(1):22-30. PubMed ID: 16932624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel therapeutic agents for systemic lupus erythematosus.
    Gescuk BD; Davis JC
    Curr Opin Rheumatol; 2002 Sep; 14(5):515-21. PubMed ID: 12192247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis.
    Lanata CM; Mahmood T; Fine DM; Petri M
    Lupus; 2010 Jul; 19(8):935-40. PubMed ID: 20388722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.